{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:02:21Z","timestamp":1792515741107,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina de Familia. SEMERGEN"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.semerg.2023.102018","type":"journal-article","created":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T07:48:30Z","timestamp":1687420110000},"page":"102018","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"S1","title":["Nefroprotecci\u00f3n cl\u00e1sica: inhibidores del sistema renina angiotensina aldosterona"],"prefix":"10.1016","volume":"49","author":[{"given":"M.I.","family":"Egocheaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Drak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Otero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semerg.2023.102018_bib0220","first-page":"1220","article-title":"The use of renin-angiotensin system inhibitors in patients with chronic kidney disease","volume":"35","author":"Leon","year":"2019","journal-title":"Can J Cardiol."},{"key":"10.1016\/j.semerg.2023.102018_bib0225","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","year":"2013","journal-title":"Kidney Int Suppl."},{"key":"10.1016\/j.semerg.2023.102018_bib0230","first-page":"39E","article-title":"Bloqueo combinado del SRAA en la enfermedad CV. \u00bfQu\u00e9 sab\u00edamos hasta ahora?","volume":"8","author":"Galve","year":"2008","journal-title":"Rev Esp Cardiol Supl."},{"key":"10.1016\/j.semerg.2023.102018_bib0235","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00041552-199601000-00015","article-title":"Renal responses to antagonism of the renin-angiotensin system","volume":"5","author":"Braam","year":"1996","journal-title":"Curr Opin Nephrol Hypertens."},{"key":"10.1016\/j.semerg.2023.102018_bib0240","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0272-6386(00)70324-6","article-title":"The role of angiotensin II and plasminogen activator inhibitor-1 in progressive glomerulosclerosis","volume":"35","author":"Fogo","year":"2000","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.semerg.2023.102018_bib0245","doi-asserted-by":"crossref","first-page":"129","DOI":"10.7326\/0003-4819-118-2-199301150-00009","article-title":"Effect of antihypertensive therapy on the kidney in persons with diabetes: A meta-regression analysis","volume":"118","author":"Kasiske","year":"1993","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.semerg.2023.102018_bib0250","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1053\/ajkd.2002.36005","article-title":"High-dose ACE inhibition: Can it improve renoprotection?","volume":"40","author":"Navis","year":"2002","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.semerg.2023.102018_bib0255","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1681\/ASN.2008040416","article-title":"Supramaximal dose of candesartan in proteinuric renal disease","volume":"20","author":"Burgess","year":"2009","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.semerg.2023.102018_bib0260","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.medcli.2021.01.007","article-title":"Maximum doses of renin-angiotensin axis blockers in diabetic nephropathy? [\u00bfDosis m\u00e1ximas de bloqueantes del eje renina-angiotensina en nefropat\u00eda diab\u00e9tica?]","volume":"157","author":"Robles P\u00e9rez-Monteoliva","year":"2021","journal-title":"Med Clin."},{"key":"10.1016\/j.semerg.2023.102018_bib0265","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/01.ASN.0000060804.40201.6E","article-title":"Mechanism of increased angiotensin II levels in glomelular mesangial cells cultured in high glucose","volume":"14","author":"Singh","year":"2003","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.semerg.2023.102018_bib0270","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin converting-enzyme inhibition on diabetic nephropathy","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semerg.2023.102018_bib0275","doi-asserted-by":"crossref","first-page":"370","DOI":"10.7326\/0003-4819-134-5-200103060-00009","article-title":"Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data","volume":"134","year":"2001","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.semerg.2023.102018_bib0280","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1136\/bmj.38237.585000.7C","article-title":"Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: Systemic review","volume":"329","author":"Strippoli","year":"2004","journal-title":"BMJ."},{"key":"10.1016\/j.semerg.2023.102018_bib0285","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1592\/phco.23.7.909.32726","article-title":"Angiotensin-converting enzyme inhibitors and type 2 diabetic nephropathy: A meta-analysis","volume":"23","author":"Hamilton","year":"2003","journal-title":"Pharmacotherapy."},{"key":"10.1016\/j.semerg.2023.102018_bib0290","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1136\/bmj.38237.585000.7C","article-title":"Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review","volume":"329","author":"Strippoli","year":"2004","journal-title":"BMJ."},{"key":"10.1016\/j.semerg.2023.102018_bib0295","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1681\/ASN.2004080634","article-title":"Antihypertensive agents for primary prevention of diabetic nephropathy","volume":"16","author":"Strippoli","year":"2005","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.semerg.2023.102018_bib0300","series-title":"Brenner y Rector. El ri\u00f1\u00f3n","first-page":"1946","article-title":"Clasificaci\u00f3n y manejo de la enfermedad renal cr\u00f3nica","author":"Taal","year":"2021"},{"key":"10.1016\/j.semerg.2023.102018_bib0305","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semerg.2023.102018_bib0310","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semerg.2023.102018_bib0315","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semerg.2023.102018_bib0320","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1161\/01.CIR.0000024416.33113.0A","article-title":"Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. A blood pressure-independent effect","volume":"106","author":"Viberti","year":"2002","journal-title":"Circulation."},{"key":"10.1016\/j.semerg.2023.102018_bib0325","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.2337\/dc06-1998","article-title":"Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes","volume":"30","author":"Makino","year":"2007","journal-title":"Diabetes Care."},{"key":"10.1016\/j.semerg.2023.102018_bib0330","doi-asserted-by":"crossref","unstructured":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney International 2022; 102 (Suppl 5S), S1-S127. Disponible en: https:\/\/kdigo.org\/wp-content\/uploads\/2022\/10\/KDIGO-2022-Clinical-Practice-Guideline-for-Diabetes-Management-in-CKD.pdf","DOI":"10.1016\/j.kint.2022.06.008"},{"key":"10.1016\/j.semerg.2023.102018_bib0335","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group (2021). KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney international 2021; 99(3S): S1-S87. Disponible en: https:\/\/doi.org\/10.1016\/j.kint.2020.11.003","DOI":"10.1016\/j.kint.2020.11.003"},{"key":"10.1016\/j.semerg.2023.102018_bib0340","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy","volume":"349","year":"1997","journal-title":"Lancet."},{"key":"10.1016\/j.semerg.2023.102018_bib0345","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA."},{"key":"10.1016\/j.semerg.2023.102018_bib0350","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1681\/ASN.2006101081","article-title":"Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease","volume":"18","author":"Kent","year":"2007","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.semerg.2023.102018_bib0355","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-135-2-200107170-00007","article-title":"Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data","volume":"135","author":"Jafar","year":"2001","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.semerg.2023.102018_bib0360","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.2215\/CJN.11511114","article-title":"Albuminuria is an appropriate therapeutic target in patients with CKD: The pro view","volume":"10","author":"Lambers Heerspink","year":"2015","journal-title":"Clin J Am Soc Nephrol."},{"key":"10.1016\/j.semerg.2023.102018_bib0365","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007751.pub2","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease","author":"Sharma","year":"2011","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.semerg.2023.102018_bib0370","doi-asserted-by":"crossref","first-page":"72","DOI":"10.2165\/00002018-199615010-00006","article-title":"ACE inhibitor-induced cough and bronchospasm. Incidence, mechanisms and management","volume":"15","author":"Overlack","year":"1996","journal-title":"Drug Saf."},{"key":"10.1016\/j.semerg.2023.102018_bib0375","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1161\/HYPERTENSIONAHA.120.16667","article-title":"Comparative First-Line Effectiveness and Safety of ACE (Angiotensin-Converting Enzyme) Inhibitors and Angiotensin Receptor Blockers: A multinational cohort study","volume":"78","author":"Chen","year":"2021","journal-title":"Hypertension."},{"key":"10.1016\/j.semerg.2023.102018_bib0380","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semerg.2023.102018_bib0385","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semerg.2023.102018_bib0390","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1001\/archinte.167.18.1930","article-title":"Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: A quantitative review of data from randomized clinical trials","volume":"167","author":"Phillips","year":"2007","journal-title":"Arch Intern Med."},{"key":"10.1016\/j.semerg.2023.102018_bib0395","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet."},{"key":"10.1016\/j.semerg.2023.102018_bib0400","unstructured":"Chronic kidney disease: Assessment and management NICE guideline [NG203] [consultado 31 Ago 2022]. Disponible en: https:\/\/www.nice.org.uk\/guidance\/ng203\/resources"},{"key":"10.1016\/j.semerg.2023.102018_bib0405","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s12325-021-02006-z","article-title":"Treatments for chronic kidney disease: A systematic literature review of randomized controlled trials","volume":"39","author":"Garcia Sanchez","year":"2022","journal-title":"Adv Ther."},{"key":"10.1016\/j.semerg.2023.102018_bib0410","doi-asserted-by":"crossref","first-page":"645187","DOI":"10.3389\/fmed.2021.645187","article-title":"Therapeutic insights in chronic kidney disease progression","volume":"8","author":"Shabaka","year":"2021","journal-title":"Front Med (Lausanne)."},{"key":"10.1016\/j.semerg.2023.102018_bib0415","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1161\/CIRCULATIONAHA.120.051898","article-title":"Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes","volume":"143","author":"Filippatos","year":"2021","journal-title":"Circulation."},{"key":"10.1016\/j.semerg.2023.102018_bib0420","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/archinte.160.5.685","article-title":"Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: Is this a cause for concern?","volume":"160","author":"Bakris","year":"2000","journal-title":"Arch Intern Med."},{"key":"10.1016\/j.semerg.2023.102018_bib0425","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.kint.2019.09.018","article-title":"Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"97","author":"Clase","year":"2020","journal-title":"Kidney Int."},{"key":"10.1016\/j.semerg.2023.102018_bib0430","unstructured":"Garc\u00eda Montemayor V, Sanchez-Agesta Mart\u00ednez M, \u00c1lvarez de Lara MA. Nefrolog\u00eda al d\u00eda. Ajuste de F\u00e1rmacos en la Enfermedad Renal Cr\u00f3nica [consultado Oct 2022]. Disponible en: https:\/\/www.nefrologiaaldia.org\/325"}],"container-title":["Medicina de Familia. SEMERGEN"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1138359323000977?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1138359323000977?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T04:42:33Z","timestamp":1761108153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1138359323000977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":43,"alternative-id":["S1138359323000977"],"URL":"https:\/\/doi.org\/10.1016\/j.semerg.2023.102018","relation":{},"ISSN":["1138-3593"],"issn-type":[{"value":"1138-3593","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nefroprotecci\u00f3n cl\u00e1sica: inhibidores del sistema renina angiotensina aldosterona","name":"articletitle","label":"Article Title"},{"value":"Medicina de Familia. SEMERGEN","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semerg.2023.102018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Sociedad Espa\u00f1ola de M\u00e9dicos de Atenci\u00f3n Primaria (SEMERGEN). Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102018"}}